Launching an effort to cure Pediatric Brain Tumors
More than 4,600 American children hear the words “brain tumor” uttered by their doctors every year. For those patients and their families, the impact of this diagnosis is overwhelming and life-changing forever. Pediatric brain tumors are the leading cause of cancer deaths in all youth aged 19 and under. For high-grade pediatric gliomas, the diagnosis is particularly grim. For one type called DIPG, most patients survive nine months, or about as long as the typical school year. And overall, only around 25% of all those with high-grade gliomas survive more than 5 years, rates that trend on par with where they were 40 years ago. There currently is no standard of care for these kids. This is completely unacceptable.
The harsh realities of pediatric brain tumors, however, are set against the promising backdrop of advances and innovation in the research of pediatric cancers as a whole. Through the power of molecular biology and genetic sequencing, we now know more than ever before about the makeup and biology of these tumors. And by applying that knowledge, new therapies could be developed that not only improve a child’s overall survival, but could lead to new treatments that can offer cures.
“The urgency of this pediatric brain tumor problem is very compelling. There is a huge sense of urgency, the time is now, as technology improvements, new treatment techniques and highly-respected researchers in their field are all coming together for the first time to help us tackle this challenge.”
– Dr. Susan Blaney, MD Texas Children’s Cancer and Hematology Centers
These advances are clear signs that progress can be made for children with brain tumors. National Brain Tumor Society is committed to increasing the survival rates of children with high-grade gliomas and shining a bright spotlight into this dark corner of pediatric cancer.
Through Project Impact: A Campaign to Defeat Pediatric Brain Tumors, National Brain Tumor Society will drive the discovery of more therapeutic options for pediatric brain tumor clinical trials, and enable them to be delivered to patients more quickly. In doing so, the National Brain Tumor Society will empower the development of the first ever standard of care for pediatric high-grade gliomas. We ask you to please invest in this critical effort to help cure these kids. Your generous donations or legacy giving will help generate new research that could lay the path directly to better treatments and ultimate a cure. Please join us now.
“We’ve entered a new era of opportunity due to new understanding of the molecular-basis of brain tumors to dramatically change therapies. Before NBTS took up the charge, there was not yet this uniform sharing of specimens and information in real time. NBTS has approached this framework in the right way to lay the groundwork for new treatments.”
– Dr. Roger Packer, MD Children’s National Hospital, Washington DC